Polyvalent Influenza Virus-Like Particles (VLPs) and Use as Vaccines


This virus-like particle (VLP) vaccine technology for influenza viruses, based on a mixture of VLPs expressing the hemagglutinin protein or the neuraminidase protein from influenza virus strains belonging to different virus subtypes, has demonstrated broad protection against lethal challenge in mice with various influenza virus strains and virus subtypes. Results from ferret and mouse studies demonstrate broad heterosubtypic protection against various influenza virus subtypes further supporting and strengthening the proposed application of this technology as a universal influenza virus vaccine.

Potential Commercial Applications: Competitive Advantages:
  • Vaccines
 
  • Broad/universal protection against influenza viruses
  • Does not require reformulating vaccine each year as is currently necessary with vaccines available on the market
  • Can potentially provide protection against novel influenza viruses that may arise in the future, including potentially pandemic influenza viruses


Inventors:

Jeffrey Taubenberger (NIAID)  ➽ more inventions...


Intellectual Property:
US Application No. 15/317,593
PCT Application No. PCT/US2015/029843
US Application No. 62/014,821

Publications:
Schwartzman LM, et al. PMID 26199334

Collaboration Opportunity:

The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this invention, especially for GMP manufacture and clinical evaluation. For collaboration opportunities, please contact Jenish Patel at jenish.patel@nih.gov or 240-669-2894.


Licensing Contact:
Jenish Patel, Ph.D.
Email: jenish.patel@nih.gov
Phone: 240-669-2894

OTT Reference No: E-195-2014/0
Updated: Dec 1, 2016